Epidemiological data are consistent in demonstrating that users of GLP-1RAs have reduced risk of developing PD, ranging from 25%50% risk reduction compared with users of other oral T2DM medications (138, 152, 153)
Balasubramanian, K
For patients who struggle with obesity, which is linked to diabetes, heart disease, and reduced life expectancy, the denial of coverage for a drug like Foundayo can be much more than frustrating it can adversely alter lives
Clinical Evidence for Non-Diabetic Weight Loss The STEP trials, which enrolled predominantly non-diabetic participants, demonstrated that semaglutide produces average weight loss of 1022% of body weight over 68 weeks, depending on dose level
Some patients may benefit from cycling the treatment (e.g., 5 days on, 2 days off) or adjusting injection timing for better results